ZA895343B - Method of treating neurological disorders - Google Patents

Method of treating neurological disorders

Info

Publication number
ZA895343B
ZA895343B ZA895343A ZA895343A ZA895343B ZA 895343 B ZA895343 B ZA 895343B ZA 895343 A ZA895343 A ZA 895343A ZA 895343 A ZA895343 A ZA 895343A ZA 895343 B ZA895343 B ZA 895343B
Authority
ZA
South Africa
Prior art keywords
neurological disorders
treating neurological
chem
compositions
disclosed
Prior art date
Application number
ZA895343A
Other languages
English (en)
Inventor
Wei Koag Chang
Koag Chang Wei
Joel Gilbert Berger
Gilbert Berger Joel
John Welch Clader
Welch Clader John
Elijah Herman Gold
Herman Gold Elijah
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA895343B publication Critical patent/ZA895343B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA895343A 1988-07-18 1989-07-13 Method of treating neurological disorders ZA895343B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/223,739 US4973586A (en) 1986-01-16 1988-07-18 Fused benzazepines, compositions of, and medical use thereof

Publications (1)

Publication Number Publication Date
ZA895343B true ZA895343B (en) 1991-03-27

Family

ID=22837795

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA895343A ZA895343B (en) 1988-07-18 1989-07-13 Method of treating neurological disorders

Country Status (13)

Country Link
US (1) US4973586A (xx)
EP (2) EP0351733B1 (xx)
JP (1) JPH0662420B2 (xx)
KR (1) KR900701275A (xx)
AT (1) ATE131056T1 (xx)
AU (1) AU634973B2 (xx)
CA (1) CA1336823C (xx)
DE (1) DE68925004T2 (xx)
DK (1) DK302190A (xx)
ES (1) ES2080736T3 (xx)
IL (1) IL90973A (xx)
WO (1) WO1990000853A2 (xx)
ZA (1) ZA895343B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302716A (en) * 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
US5091526A (en) * 1988-07-29 1992-02-25 Schering Corporation Process for the enantiospecific synthesis of intermediates for hexahydro-benzo[d]-naphtho[2,1-b]azepines
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
ES2075429T3 (es) * 1990-02-02 1995-10-01 Schering Corp Derivados de 4,5-cicloalcano-3-benzazepin-7-ol y sus usos.
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5461148A (en) * 1993-09-27 1995-10-24 Schering Corporation Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
US5463051A (en) * 1993-09-27 1995-10-31 Schering Corporation Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
US5461147A (en) * 1993-09-27 1995-10-24 Schering Corporation Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
CA2304592A1 (en) * 1997-09-24 1999-04-01 The General Hospital Corporation Inhibition of psychostimulant-induced and nicotine-induced craving
US6410527B1 (en) 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6875866B2 (en) * 2002-02-21 2005-04-05 Schering Corporation Process for synthesis of D1 receptor antagonists
DE60321354D1 (de) * 2002-08-29 2008-07-10 Schering Corp Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen
JP2006526021A (ja) * 2003-05-22 2006-11-16 シェーリング　コーポレイション 肥満およびｃｎｓ障害を治療する選択的ｄ１／ｄ５レセプタアンタゴニストとしての５ｈ−ベンゾ［ｄ］ナフト［２，１−ｂ］アゼピン誘導体
ES2914043T3 (es) 2012-07-12 2022-06-07 Emalex Biosciences Inc Benzazepinas condensadas para el tratamiento del síndrome de tourette
SI3057595T1 (sl) 2013-10-18 2020-09-30 Emalex Biosciences, Inc. Spojeni benzazepini za zdravljenje jecljanja

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393192A (en) * 1965-04-26 1968-07-16 Schering Corp Novel benzazepines
CH481110A (de) * 1967-02-17 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
GB1118688A (en) * 1967-02-17 1968-07-03 Scherico Ltd Novel benzazepines and process for making same
US3609138A (en) * 1967-12-22 1971-09-28 Ciba Geigy Corp 1-aryl-3-benzazepines
IL39381A0 (en) * 1971-05-10 1972-07-26 Sparamedica Ag Rheadan-type alkaloids,their preparation and pharmaceutical compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
US3939165A (en) * 1974-11-14 1976-02-17 Morton-Norwich Products, Inc. 5,6,6A,6B,7,8-Hexahydrobenz[a]phenanthridine hydrochloride
US4011319A (en) * 1975-07-02 1977-03-08 Smithkline Corporation Pharmaceutical compositions and methods involving benzazepine derivatives
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4315926A (en) * 1979-12-26 1982-02-16 Ciba-Geigy Corporation Dibenz[c,e]azepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
DE3007710C2 (de) * 1980-02-29 1982-04-15 Gödecke AG, 1000 Berlin 5,6;8,9-Tetrahydro-7H-dibenz(d,f)azonin-derivate, Verfahren zu deren Herstellung und Arzneimittel
JPH0681745B2 (ja) 1986-01-16 1994-10-19 シェリング・コ−ポレ−ション 縮合ベンゾアゼピン
ATE78467T1 (de) * 1987-07-15 1992-08-15 Schering Corp Kondensierte benzazepine.

Also Published As

Publication number Publication date
ATE131056T1 (de) 1995-12-15
KR900701275A (ko) 1990-12-01
ES2080736T3 (es) 1996-02-16
EP0351733B1 (en) 1995-12-06
AU3988489A (en) 1990-02-19
DK302190D0 (da) 1990-12-20
EP0434695A1 (en) 1991-07-03
JPH03502100A (ja) 1991-05-16
EP0351733A1 (en) 1990-01-24
DE68925004T2 (de) 1996-05-15
JPH0662420B2 (ja) 1994-08-17
DK302190A (da) 1991-01-11
AU634973B2 (en) 1993-03-11
WO1990000853A8 (en) 2005-06-16
US4973586A (en) 1990-11-27
DE68925004D1 (de) 1996-01-18
WO1990000853A2 (en) 1990-02-08
CA1336823C (en) 1995-08-29
IL90973A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
ZA895343B (en) Method of treating neurological disorders
HU896762D0 (en) Process for preparation of pyrimidine-derivatives and for manufacturing of pharmaceutical compositions containing these compounds
UA72881C2 (uk) Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
LV10262B (en) Process for producing pharmaceutical compounds
HU0301601D0 (en) Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof
IL90102A0 (en) Fused polycyclic compounds,method of manufacture,and their use as paf antagonists,antihistamines and/or antiinflammatory agents
MX9602517A (es) Naftiloamidas como agentes del sistema nervioso central.
GB9212308D0 (en) Therapeutic compositions
GR3019782T3 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
HUT45960A (en) Process for producing 2,4,5-trisubstituted derivatives of phenol of antiflogistic activity
PT693070E (pt) Pirido(2,3-b)(1,4)benzodiazepinonas como ligando do receptor m2 para o tratamento de desordens neurologicas
PH27326A (en) Substituted cyclohexenes as central nervous system agents
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
AU4868490A (en) 3- or 4-substituted oxotremorine derivatives
HUT45967A (en) Process for production of antipasmodic derivatives of n-/substituated phenil/-benzoil-amid
ZA875183B (en) Fused benzazepines
CS53688A2 (en) Method of new substituted 3-phenyl-7h-thiazolo/3,2-b//1,2,4/triazine -7-ons production
DK0430035T3 (da) Anvendelse af benzothiazepiner til fremstilling af lægemidler til behandling af epileptiske anfald
ATE116320T1 (de) 5,11-dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin 6-one und -thione und deren verwendung bei der vorbeugung und und behandlung von aids.
GR3007119T3 (xx)
LV5780A4 (lv) Pretkonvulsiju triazoÚ4,5-c¾piridina atvasinajumi